IDEAYA Biosciences, Inc.
IDYA
주식 순위
#4579
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
주가
$35.09
시가총액
$3.39B
변동 (1일)
3.79%
변동 (1년)
15.01%
국가
US
거래 IDEAYA Biosciences, Inc. (IDYA)
카테고리
Healthcare
IDEAYA Biosciences, Inc. (IDYA)의 수익
Jun 2026 기준 수익 TTM: $-175.02M
IDEAYA Biosciences, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-175.02M입니다. 2023년에 회사는 $-112.96M의 수익을 올렸으며 이는 2022년의 수익 $-58.66M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
IDEAYA Biosciences, Inc.의 수익 기록 (2017 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-175.02M | -36.24% |
| 2024 | $-274.48M | 142.98% |
| 2023 | $-112.96M | 92.59% |
| 2022 | $-58.66M | 17.87% |
| 2021 | $-49.76M | 44.26% |
| 2020 | $-34.50M | -17.82% |
| 2019 | $-41.98M | 22.21% |
| 2018 | $-34.35M | 189.55% |
| 2017 | $-11.86M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | -3,113.88% |
US
|
|
| $-3.09B | 1,663.80% |
US
|
|
| $-4.02B | 2,194.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,214.53% |
NL
|
